Registration - Consultant

Subject Matters

• Agriculture
• Budget
• Consumer Issues
• Economic Development
• Employment and Training
• Energy
• Environment
• Fisheries
• Forestry
• Government Procurement
• Health
• Immigration
• Industry
• Intellectual Property
• International Relations
• International Trade
• Research and Development
• Science and Technology
• Small Business
• Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution

• CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologies
• FOOD AND DRUGS ACT AND REGULATIONS in respect of minimizing regulatory burden and ensuring appropriate climate for the introduction of new technologies

Policies or Program

• ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
• ADVENTITIOUS PRESCENCE POLICY in respect of new agricultural biotechnology products
• BIOSAFETY PROTOCOL in respect of Canada's participation in global discussions to ensure an enabling environment for safe new technologies
• Clarify the administration of SR&ED ( Scientific Research and Experimental Development) program to ensure clinical trials and international research conducted in Canada qualifies as eligible expenses
• Creation of a modern policy environment that recognizes international standards and reviews, and establishes clarity on data ownership for intellectual property
• Establish accountability with the federally financed Canadian Agency for Drugs and Technologies and Health (CADTH) and its Common Drug Review process (Health Canada)
• FOOD LABELLING in respect of mitigating the unnecessary introduction of new labelling requirements for products already approved under current regulated process and in respect of maintaining harmonization of requirements with trading nations
• IMPROVED TAXATION & INVESTMENT FRAMEWORK in respect of extending Canada's flow-through shares program to biotechnology companies for increased domestic investments.
• IMPROVEMENTS TO THE Scientifc Research & Experimental Development TAX CREDITS in respect of updating the 20 yr old system by removing the punitive Canadian Controlled Private Companies restriction and increasing the expenditure limit for refundable credits
• INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA (Canada-European Union Comprehensive Economic and Trade Agreement) negotiations)
• NOVEL FOODS in respect of maintaining a science-based regulatory system for novel foods derived from plant and animal biotechnology
• PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada
• REGULATORY APPROVAL PROCESS FOR PLANTS WITH NOVEL TRAITS as NOVEL FOODS or INDUSTRIAL BIO_PRODUCTS in respect of an efficient science-based approach and allows for greater cooperation among and between government departments
• RESEARCH & DEVELOPMENT (R&D) in respect on providing input to the government's expert panel on business R&D to improve incentives for research in Canada
• Regulatory framework for subsequent entry biologics to ensure an appropriate and transparent appraoch for the safe introduction of biosimilars
• SCIENCE & TECHNOLOGY STRATEGY in respect of encouraging a strong government focus to stimulate the development, use and retention of biotechnology products, processes and companies
• SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantage
• Vaccine Funding - National Immunization Strategy - to re-establish federal leadership in providing provinces with funding for new vaccines under a renewed national immunization strategy framework
• WORLD TRADE ORGANIZATION (WTO) in respect of Canada's contribution and participation to encourage a sound business climate and to faciliate Canada's access to European markets for genetically engineered agricultural and animal products

Policies or Program, Regulation

• ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases

Regulation

• SUBSEQUENT ENTRY BIOLOGICS to establish formal regulations to prescribe the requirements for introduction of biosimilars and ensure the protection of intellectual property for first entry biologics

Communication Techniques

• Written communication
• Oral communication

Government Institutions

• Agriculture and Agri-Food Canada (AAFC)
• Atlantic Canada Opportunities Agency (ACOA)
• Business Development Bank of Canada (BDC)
• Canada Economic Development for Quebec Regions
• Canada Pension Plan Investment Board
• Canada Revenue Agency (CRA)
• Canadian Food Inspection Agency (CFIA)
• Canadian Institutes of Health Research (CIHR)
• Employment and Social Development Canada (ESDC)
• Environment and Climate Change Canada (ECCC)
• Export Development Canada (EDC)
• Federal Economic Development Agency for Southern Ontario (FedDev)
• Finance Canada (FIN)
• Fisheries and Oceans Canada (DFO)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Immigration, Refugees and Citizenship Canada (IRCC)
• Innovation, Science and Economic Development Canada (ISED)
• National Research Council (NRC)
• Natural Resources Canada (NRCan)
• Natural Sciences and Engineering Research Council (NSERC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Senate of Canada
• Social Sciences and Humanities Research Council (SSHRC)
• Statistics Canada (StatCan)
• Treasury Board Of Canada Secretariat (TBS)
• Western Economic Diversification Canada (WD)

Address:
600 - 1 NICHOLAS STREET
Ottawa, ON  K1N 7B7
Canada

Telephone number: 613-230-5585

Client representative

Andrew Casey, President & CEO

Parent Company Information

BIOTECANADA is not a subsidiary of any other parent companies.